Return to About
  Advisory Board

Josh Silvertown, PhD, MBA - Founder: Dr. Josh Silvertown is a leading authority in relaxin cancer biology. He has over 17 years of experience in preclinical drug research and development and is the lead inventor of Armour's relaxin-antagonist technology. During his years in translational and biomedical research, Josh published over 30 scientific works, including publications in notable endocrinology and oncology journals, and is an inventor on 23 issued or pending patents. Josh has had experience in executive management (corporate and global business development) and consulting (clinical research, strategy, and medical communications) roles for biopharma, biotech and medical device companies in Canada, the US and Europe. Josh spent three years as an NSERC Post-Doctoral Fellow conducting prostate cancer research at the Ontario Cancer Institute, University Health Network in Toronto. Josh is a graduate of the Ivey School of Business at Western University, where he completed an MBA, specializing in the Health Sector as a Canadian Institute of Health Research "Science-to-Business" Fellow. He also holds a PhD in Biomedical Sciences and an Honours BSc in Molecular Biology and Genetics from the University of Guelph. Josh is an Action Canada Fellow of 2004 and was chosen as a "Top 40 Under 40" in the medtech sector by the Medical Device and Diagnostic Industry (MDDI) in 2012.

Har Grover, BSc, MBA - Chair of Board of Directors: Har is the Managing Director of Nucleus GC, a specialized advisory and investment company. As an entrepreneur and senior executive, he has built and grown companies at all stages, from start-up to commercialization, to going public and growing through the $1 billion revenue mark. Over a 25+ year career in both Canada and the United States, he has created double and triple digit growth through strategic transactions, entering new markets in North America, and sales and marketing strategies. He has played a key role in launching a number of technologies including those used in the diagnosis and treatment of prostate cancer. He has also helped several North American life sciences companies to achieve successful exits through strategic buyouts. His deal sheet includes mergers/acquisitions, strategic alliances, private equity financings, spin-out/divestitures, out-licensing, in-licensing, start-ups and equity restructurings. Har serves on a number of boards of both public and private companies and non-profit organizations including the Crohn's and Colitis Foundation of Canada. He has an undergraduate degree in the medical sciences, an MBA, Certified Management Consultant (CMC) and Certified Board Director (ICD.D).

Shawn K. Singh, JD: Shawn is the CEO of VistaGen Therapeutics, a biotechnology company applying pluripotent stem cell technology for drug rescue and stem cell therapy. Mr. Singh joined the VistaGen Board of Directors in 2000 and its senior management team (part-time) in 2003 following their acquisition of Artemis Neuroscience, of which he was President. Mr. Singh has 20 years of experience working with public and private biotechnology and pharmaceutical companies. From February 2001 to August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, a life science venture capital firm, and as Chief Business Officer and General Counsel of Cato Research, a global CRO affiliated with Cato BioVentures. Mr. Singh also served as President (part-time) of Echo Therapeutics, Inc. (OTCBB: ECTE) from September 2007 to June 2009 and as CEO (part-time) of Hemodynamic Therapeutics, a majority-owned affiliate of Cato BioVentures, from November 2004 to August 2009. From late-2000 to February 2001, Mr. Singh served as Managing Director of Start-Up Law, a management consulting firm serving early-stage biotechnology companies. Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN) from late-1993 to late-2000 and as a corporate finance associate of Morrison & Foerster LLP, an international law firm from 1991 to late-1993. Mr. Singh also currently serves as a member of the Board of Directors of Echo Therapeutics (OTCBB: ECTE), Armour Therapeutics Inc, and Hemodynamic Therapeutics. Mr. Singh is a member of the State Bar of California.


© 2016 Armour Therapeutics Inc. All Rights Reserved.